Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

This publication has 14 references indexed in Scilit:

• A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
  Clinical Cancer Research, 2012
• 7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
  European Journal Of Cancer, 2011
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
  International Journal of Cancer, 2010
• Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites
  Cancer Research, 2010
• Evolving Treatment of Advanced Colorectal Cancer
  Current Oncology Reports, 2010
• DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study
  Journal of Angiogenesis Research, 2009
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal Of Cancer, 2009
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
  Annals of Oncology, 2007
• Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2007
• Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2004